# Hyogo University

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/hyogo-university/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 50.7 |
| Citations | 68,499 |
| City | Kakogawa |
| Country | JP |
| Description | Hyogo University is a research organisation in Kakogawa, JP. OpenAlex records 4,247 works and 68,499 citations for it. 1,817 researchers list it as their most recent affiliation. |
| Homepage | http://www.hyogo-dai.ac.jp/ |
| OpenAlex ID | https://openalex.org/I84059937 |
| Researchers | 1,817 |
| ROR ID | https://ror.org/024pdem44 |
| Type | education |
| Wikidata ID | https://www.wikidata.org/wiki/Q1641740 |
| Works | 4,247 |

## University papers

Showing 12 of 13.

- [Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study](https://scholariq.org/papers/early-immune-related-adverse-events-and-association-with-outcome-in-advanced-non/)
- [Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis](https://scholariq.org/papers/elevated-serum-myostatin-level-is-associated-with-worse-survival-in-patients/)
- [Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor](https://scholariq.org/papers/efficacy-of-osimertinib-plus-bevacizumab-vs-osimertinib-in-patients-with-i-egfr/)
- [“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy](https://scholariq.org/papers/interchangeability-of-pd-l1-immunohistochemistry-assays-a-meta-analysis-of/)
- [Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L](https://scholariq.org/papers/randomized-phase-iii-study-comparing-gefitinib-with-erlotinib-in-patients-with/)
- [Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study](https://scholariq.org/papers/randomized-phase-2-study-of-osimertinib-plus-bevacizumab-versus-osimertinib-for/)
- [Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study](https://scholariq.org/papers/efficacy-and-safety-of-nivolumab-in-previously-treated-patients-with-non-small/)
- [Usefulness of Attenuation Imaging with an Ultrasound Scanner for the Evaluation of Hepatic Steatosis](https://scholariq.org/papers/usefulness-of-attenuation-imaging-with-an-ultrasound-scanner-for-the-evaluation/)
- [Pseudoprogression in Previously Treated Patients with Non–Small Cell Lung Cancer Who Received Nivolumab Monotherapy](https://scholariq.org/papers/pseudoprogression-in-previously-treated-patients-with-non-small-cell-lung-cancer/)
- [Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial](https://scholariq.org/papers/nivolumab-for-advanced-non-small-cell-lung-cancer-patients-with-mild-idiopathic/)
- [Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients](https://scholariq.org/papers/alteration-of-pd-l1-expression-and-its-prognostic-impact-after-concurrent/)
- [Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer](https://scholariq.org/papers/characteristics-and-prognostic-impact-of-pneumonitis-during-systemic-anti-cancer/)

## University researchers

- [Daichi Fujimoto](https://scholariq.org/researchers/daichi-fujimoto/)

## University top topics

Showing 8 of 25.

- [Acute Ischemic Stroke Management](https://scholariq.org/topics/acute-ischemic-stroke-management/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cerebrovascular and Carotid Artery Diseases](https://scholariq.org/topics/cerebrovascular-and-carotid-artery-diseases/)
- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Intracranial Aneurysms: Treatment and Complications](https://scholariq.org/topics/intracranial-aneurysms-treatment-and-complications/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.